Lyme Borrelia Nanotrap® Urine Antigen Test

Enhanced Sensitivity for Accurate Detection

Conventional Lyme tests rely on the body’s immune response to detect infection, but Borrelia actively suppresses that very response and hides in protected areas of the body. As a result, many patients go undiagnosed.

The Diagnostic Challenge of Lyme Disease

Lyme disease (Borreliosis) is notoriously tricky to diagnose. Traditional testing relies on detecting antibodies, meaning early-stage or persistent infections can go undetected. Borrelia often circulates at very low levels and hides in tissues, making blood-based diagnostics unreliable, especially outside the acute phase.

Because antibody responses take time or may be blunted, patients may test negative despite ongoing infection. That’s why Galaxy’s antigen direct detection strategy bypasses those limitations.

Galaxy’s Direct Detection: Nanotrap® Technology

The Lyme Borrelia urine antigen test uses proprietary Nanotrap® particles to isolate and concentrate the Borrelia OspA antigen.

Licensed via Ceres Nanosciences, this method boosts sensitivity by capturing the molecular signature of the pathogen from urine.

Because the test doesn’t depend on antibody response, it offers an advantage in detecting current presence of a pathogen even when bacterial loads are very low.

This makes Nanotrap® especially valuable in settings where standard testing fails or yields ambiguous results.

What Makes It Different:

High Sensitivity: Detects extremely low concentrations of Borrelia OspA protein
Early Detection: Useful in both acute and chronic cases
Non-Invasive Collection: Single urine sample, no blood draw required
Actionable Results: Supports diagnosis and evaluation of persistent symptoms

When to Order the Lyme Borrelia Urine Antigen Test

Ideal Use Cases:

This test offers clarity when serology is inconclusive and gives additional data for high-stakes clinical decisions.

Why Direct Detection Matters

Antibody-based methods rely on the immune system, they detect exposure, not current pathogen presence. In early disease or immunocompromised patients, those responses may not yet exist or may be suppressed.

Nanotrap® technology shifts the focus to pathogen antigen, revealing current presence of Lyme Borrelia rather than past immune memory. This distinction can mean earlier detection, better treatment decisions, and more confidence in complex cases.

Complementary Testing & The Galaxy Advantage

Complementary Test Strategies

Lyme Borrelia Direct Detect + BBB Direct Detect:

Together, these tests provide comprehensive coverage across Borrelia species. Relapsing Fever Borrelia circulate in blood and are best captured by BBB Direct Detect, while Lyme Borrelia often reside in tissues and are more effectively identified through Nanotrap® urine antigen testing.
Our BBB panel also includes Babesia and Bartonella, co-infections that can occur with or without Borrelia, providing a broader view of vector-borne disease.

Why Galaxy’s Nanotrap® Approach Stands Out

The Result: Clarity in Complex Cases

Galaxy’s Nanotrap® test brings a much-needed tool to Lyme diagnostics. By detecting Borrelia antigen directly, providers gain real-time insight into current presence of a pathogen, not just immune history. This leads to more precise treatment decisions, especially in early or persistent cases where serology falls short.

Trusted by Healthcare Providers Nationwide

“Galaxy Diagnostics is the single best test you can order to manage stealth infections. It’s a reliable, leading-edge tool that stretches a provider’s ability to diagnose accurately where others fall short.”

— Dr. Jay Stevens, Essential Health

“Galaxy has been the most consistently helpful tool in confirming Bartonella exposure and guiding effective treatment — often when other labs miss it.”

— Dr. Maria Marian, Jyzen

“What sets Galaxy apart is their science and their partnership, they don’t just deliver results, they help me contextualize them so I can treat patients with clarity and confidence.”

— Dr. Tonya Cramer, Essential Health

“What gives me confidence in this testing is the strength of the underlying science—the reproducibility, the specificity, and the rigor of the methodology. That combination makes it a more reliable and clinically actionable tool.”

— Dr. Casey Kelley, MD, ABoIM, Founder, Case Integrative Health

“Galaxy’s direct detection gives my team the clarity we need. Their science, education, and partnership have changed how we approach complex tick-borne cases. When I need objective data, not just a panel that lights up, Galaxy is the gold standard.”

— Dr. Chris Turnpaugh, Turnpaugh Health & Wellness

“Galaxy is leading the field in stealth pathogen diagnostics, not just with innovation, but with transparency and trust.”

—Dr. Shannon Smith, Turnpaugh Health & Wellness